AUA 2022 Bladder Cancer - Results from #40

Viewing 41-56 of 56 articles

AUA 2022: Interim Analysis: IV Vitamin C with Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

AUA 2022: Modeling the Contribution of Preoperative VI-RADS Score to Predict Final Pathologic Lymph-Nodes Involvement in Patients with MIBC Undergone Radical Cystectomy

AUA 2022: The Accuracy of (VI-RADS): An Updated Comprehensive Multi-Institutional, Multi-Readers Systematic Review and Meta-Analysis From Diagnostic Evidence Into Future Clinical Recommendations

AUA 2022: Whitmore Lecture

AUA 2022: Sequential Intravesical Gemcitabine and Docetaxel for BCG-Naïve High-Risk NMIBC

AUA 2022: Adjuvant Therapy after Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma

AUA 2022: Real-time Bladder Tumor Detection at Clinics in Flexible Cystoscopy with White Light and Narrow Band Imaging using Deep Learning

AUA 2022: En-Bloc Versus Conventional Transurethral Resection of Bladder Tumors: Single-Center Prospective Randomized Trial

AUA 2022: A Randomized Study to Compare Outcomes of Intravesical Chemohyperthermia with Mitomycin C Versus Intravesical BCG for Intermediate and High Risk NMIBC

AUA 2022: Is A Restaging TURBT Necessary in High Risk NMIBC if the Initial TURBT Was Performed Using Blue Light?

AUA 2022: Long-term Follow-up of Intravesical Gemcitabine and Docetaxel as Rescue Therapy for NMIBC

AUA 2022: Women in Urologic Oncology: Past, Present, and Future

AUA 2022: Survivor Debate: NMIBC Refractory BCG: Cystectomy, Systemic Immunotherapy, Intravesical Chemotherapy

AUA 2022: Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts

AUA 2022: Primary Versus Secondary Muscle Invasive Bladder Cancer: Comparing the Pathologic and Oncologic Outcomes Between Both Forms of Muscle Invasive Disease When Treated with Standard of Care

AUA 2022: Impact of Prior Intravesical Bacillus Calmette-Guerin Therapy for Non-Muscle Invasive Bladder Cancer on the Efficacy of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma

1
2
3